Secondary Logo

Journal Logo

Focus on pharmacotherapy for depression

doi: 10.1097/01.NURSE.0000615372.45228.4c
CE Connection
Free

For more than 118 additional continuing-education articles related to psychosocial/psychiatric topics, go to NursingCenter.com/CE.

Earn CE credit online: Go to www.nursingcenter.com/CE/nursing and receive a certificate within minutes.

Nursing2019 will no longer facilitate mail-in continuing-education tests. All CE tests must be taken online at www.nursingcenter.com/ce/nursing. Please address any questions to customer service at 1-800-787-8985.

Back to Top | Article Outline

INSTRUCTIONS Focus on pharmacotherapy for depression

TEST INSTRUCTIONS

  • Read the article. The test for this CE activity is to be taken online at www.nursingcenter.com/CE/nursing.
  • You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
  • There's only one correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
  • For questions, contact Lippincott Professional Development: 1-800-787-8985.
  • Registration deadline is December 3, 2021.
Back to Top | Article Outline

PROVIDER ACCREDITATION

Lippincott Professional Development will award 1.5 contact hours and 1.5 pharmacology credits for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours, and the District of Columbia, Georgia, and Florida CE Broker #50-1223.

Payment: The registration fee for this test is $17.95.

Focus on pharmacotherapy for depression

GENERAL PURPOSE: To provide an overview of depression and the first- and second-line medications used to manage it in adults. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Describe the characteristics of depression. 2. Understand the role of nurses in caring for patients with depression. 3. Identify medications indicated to manage depression.

  1. To be diagnosed with MDD, a patient must have been experiencing symptoms of depression for a minimum of
    1. 1 week.
    2. 2 weeks.
    3. 4 weeks.
  2. Diagnostic criteria for MDD include all of the following except
    1. psychomotor agitation.
    2. thoughts of guilt.
    3. high energy level.
  3. Nearly one-third of patients being treated for MDD experience
    1. complete symptom relief from psychotherapy alone.
    2. remission of symptoms after 1 week of pharmacotherapy.
    3. an inadequate response to pharmacotherapy.
  4. First-line pharmacologic therapies recommended for MDD include
    1. SSRIs.
    2. MAOIs.
    3. SARIs.
  5. Antidepressant therapy should be adjusted if a patient does not improve after how many weeks of treatment?
    1. 2 weeks
    2. 4 weeks
    3. 8 weeks
  6. QTc prolongation puts patients taking SSRIs at risk for
    1. torsades de pointes.
    2. atrioventricular blocks.
    3. bradydysrhythmias.
  7. During the first 2 weeks of therapy, the most common adverse reaction to SSRIs is
    1. somnolence.
    2. nausea.
    3. agitation.
  8. Citalopram, fluoxetine, sertraline, and escitalopram are classified as
    1. SNRIs.
    2. atypical antidepressants.
    3. SSRIs.
  9. Noradrenergic adverse reactions associated with SNRIs include
    1. bradycardia.
    2. miosis.
    3. xerostomia.
  10. Bupropion should be avoided in patients with a history of
    1. sexual dysfunction.
    2. seizures.
    3. sleep disturbances.
  11. Advise patients prescribed SARIs to take each dose
    1. in the morning.
    2. before bed.
    3. with meals.
  12. Nefazodone should be avoided in patients with
    1. hepatic failure.
    2. renal failure.
    3. increased serum creatinine.
  13. Signs of serotonin syndrome include
    1. hypothermia.
    2. muscle rigidity.
    3. areflexia.
  14. TCAs are not recommended for patients with
    1. hepatic failure.
    2. renal failure.
    3. glaucoma.
  15. Common anticholinergic adverse reactions to TCAs include
    1. blurred vision.
    2. diarrhea.
    3. frequent micturition.
  16. During the first few weeks and months of any antidepressant therapy, patients are at increased risk for
    1. hypertensive crisis.
    2. serotonin syndrome.
    3. suicidal ideation.
  17. Upon learning about a patient's suicidal ideation, what should the nurse do first?
    1. Ask about a plan.
    2. Contact a family member.
    3. Arrange for transport to a psychiatric facility.
  18. Atypical antidepressants include
    1. vortioxetine.
    2. isocarboxazid.
    3. mirtazapine.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.